Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2015

Open Access 01-12-2015 | Research

Intranasal administration of poly-gamma glutamate induced antiviral activity and protective immune responses against H1N1 influenza A virus infection

Authors: Eun-Ha Kim, Young-Ki Choi, Chul-Joong Kim, Moon-Hee Sung, Haryoung Poo

Published in: Virology Journal | Issue 1/2015

Login to get access

Abstract

Background

The global outbreak of a novel swine-origin strain of the 2009 H1N1 influenza A virus and the sudden, worldwide increase in oseltamivir-resistant H1N1 influenza A viruses highlight the urgent need for novel antiviral therapy.

Methods

Here, we investigated the antiviral efficacy of poly-gamma glutamate (γ-PGA), a safe and edible biomaterial that is naturally synthesized by Bacillus subtilis, against A/Puerto Rico/8/1934 (PR8) and A/California/04/2009 (CA04) H1N1 influenza A virus infections in C57BL/6 mice.

Results

Intranasal administration of γ-PGA for 5 days post-infection improved survival, increased production of antiviral cytokines including interferon-beta (IFN-β) and interleukin-12 (IL-12), and enhanced activation of natural killer (NK) cells and influenza antigen-specific cytotoxic T lymphocytes (CTL) activity.

Conclusions

These results suggest that γ-PGA protects mice against H1N1 influenza A virus by enhancing antiviral immune responses.
Literature
1.
Duan S, Boltz DA, Seiler P, Li J, Bragstad K, Nielsen LP, et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog. 2010;6(7):e1001022.PubMedCentralCrossRefPubMed
2.
Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007–2008 and 2008–2009 influenza seasons. Clin Infect Dis. 2009;49(12):1828–35.CrossRefPubMed
3.
Shishkina L, Skarnovich M, Kabanov A, Sergeev A, Olkin S, Tarasov S, et al. Antiviral activity of Anaferon (pediatric formulation) in mice infected with pandemic influenza virus A (H1N1/09). B Exp Biol Med. 2010;149(5):612–4.CrossRef
4.
Fernandez-Sesma A, Marukian S, Ebersole BJ, Kaminski D, Park MS, Yuen T, et al. Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol. 2006;80(13):6295–304.PubMedCentralCrossRefPubMed
5.
Hikono H, Kohlmeier JE, Ely KH, Scott I, Roberts AD, Blackman MA, et al. T‐cell memory and recall responses to respiratory virus infections. Immunol Rev. 2006;211(1):119–32.CrossRefPubMed
6.
García-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in detente. Science. 2006;312(5775):879–82.CrossRefPubMed
7.
Jiang T, Zhao H, Li XF, Deng YQ, Liu J, Xu LJ, et al. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model. Antiviral Res. 2011;89(1):124–6.CrossRefPubMed
8.
Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD. CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol. 2008;180(4):2562–72.CrossRefPubMed
9.
Norton EB, Clements JD, Voss TG, Cárdenas-Freytag L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol. 2010;84(6):2983–95.PubMedCentralCrossRefPubMed
10.
Sung MH, Park C, Kim CJ, Poo H, Soda K, Ashiuchi M. Natural and edible biopolymer poly‐γ‐glutamic acid: synthesis, production, and applications. Chem Rec. 2005;5(6):352–66.CrossRefPubMed
11.
Kim S, Yang JY, Lee K, Oh KH, Gi M, Kim JM, et al. Bacillus subtilis-specific poly-γ-glutamic acid regulates development pathways of naive CD4+ T cells through antigen-presenting cell-dependent and-independent mechanisms. Int Immunol. 2009;21(8):977–90.CrossRefPubMed
12.
Shih IL, Van YT. The production of poly-(γ-glutamic acid) from microorganisms and its various applications. Bioresour Technol. 2001;79(3):207–25.CrossRefPubMed
13.
Kim TW, Lee TY, Bae HC, Hahm JH, Kim YH, Park C, et al. Oral administration of high molecular mass poly-γ-glutamate induces NK cell-mediated antitumor immunity. J Immunol. 2007;179(2):775–80.CrossRefPubMed
14.
Lee TY, Kim YH, Yoon SW, Choi JC, Yang JM, Kim C-J, et al. Oral administration of poly-gamma-glutamate induces TLR4-and dendritic cell-dependent antitumor effect. Cancer Immunol Immunother. 2009;58(11):1781–94.CrossRefPubMed
15.
Moon HJ, Lee JS, Choi YK, Park JY, Talactac MR, Chowdhury MY, et al. Induction of type I interferon by high-molecular poly-γ-glutamate protects B6. A2G-Mx1 mice against influenza A virus. Antiviral Res. 2012;94(1):98–102.CrossRefPubMed
16.
Uto T, Akagi T, Hamasaki T, Akashi M, Baba M. Modulation of innate and adaptive immunity by biodegradable nanoparticles. Immunol Lett. 2009;125(1):46–52.CrossRefPubMed
17.
Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001;1(1):41–9.CrossRefPubMed
18.
Grayson MH, Holtzman MJ. Emerging role of dendritic cells in respiratory viral infection. J Mol Med. 2007;85(10):1057–68.CrossRefPubMed
19.
20.
Toka FN, Pack CD, Rouse BT. Molecular adjuvants for mucosal immunity. Immunol Rev. 2004;199(1):100–12.CrossRefPubMed
21.
Österlund P, Pirhonen J, Ikonen N, Rönkkö E, Strengell M, Mäkelä SM, et al. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol. 2010;84(3):1414–22.PubMedCentralCrossRefPubMed
22.
Boon A, de Mutsert G, Graus Y, Fouchier R, Sintnicolaas K, Osterhaus A, et al. The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and-B phenotype. J Virol. 2002;76(2):582–90.PubMedCentralCrossRefPubMed
23.
La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol. 2007;85(2):85–92.CrossRefPubMed
24.
Lichterfeld M, Xu GY, Waring MT, Mui SK, Johnston MN, Cohen D, et al. HIV-1–specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-γ and tumor necrosis factor–α. Blood. 2004;104(2):487–94.CrossRefPubMed
25.
Swain SL, Dutton RW, Woodland DL. T cell responses to influenza virus infection: effector and memory cells. Viral Immunol. 2004;17(2):197–209.CrossRefPubMed
26.
Eichelberger M, Allan W, Zijlstra M, Jaenisch R, Doherty P. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med. 1991;174(4):875–80.CrossRefPubMed
27.
Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T, et al. Poly (γ-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine. 2009;27(42):5896–905.CrossRefPubMed
28.
Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature. 2009;462(7272):449–60.CrossRefPubMed
29.
30.
31.
32.
Phipps-Yonas H, Seto J, Sealfon S, Moran T, Fernandez-Sesma A. Interferon-beta pretreatment of conventional and plasmacytoid human dendritic 545 cells enhances their activation by influenza virus. PLoS Pathog. 2008;4:e1000193.PubMedCentralCrossRefPubMed
33.
Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol. 2005;174(2):727–34.CrossRefPubMed
34.
Mehrotra PT, Wu D, Crim JA, Mostowski HS, Siegel J. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol. 1993;151(5):2444–52.PubMed
35.
Williman J, Young S, Buchan G, Slobbe L, Wilson M, Pang P, et al. DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza. Vaccine. 2008;26(40):5153–8.CrossRefPubMed
36.
Hogan RJ, Cauley LS, Ely KH, Cookenham T, Roberts AD, Brennan JW, et al. Long-term maintenance of virus-specific effector memory CD8+ T cells in the lung airways depends on proliferation. J Immunol. 2002;169(9):4976–81.CrossRefPubMed
37.
38.
Wiley JA, Cerwenka A, Harkema JR, Dutton RW, Harmsen AG. Production of interferon-γ by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am J Pathol. 2001;158(1):119–30.PubMedCentralCrossRefPubMed
39.
Hanna J, Gonen-Gross T, Fitchett J, Rowe T, Daniels M, Arnon TI, et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest. 2004;114(11):1612–23.PubMedCentralCrossRefPubMed
40.
Kos FJ, Engleman EG. Role of natural killer cells in the generation of influenza virus-specific cytotoxic T cells. Cell Immunol. 1996;173(1):1–6.CrossRefPubMed
41.
Ingulli E, Funatake C, Jacovetty EL, Zanetti M. Cutting edge: antigen presentation to CD8 T cells after influenza A virus infection. J Immunol. 2009;182(1):29–33.CrossRefPubMed
42.
Sun P, Celluzzi CM, Marovich M, Subramanian H, Eller M, Widjaja S, et al. CD40 ligand enhances dengue viral infection of dendritic cells: a possible mechanism for T cell-mediated immunopathology. J Immunol. 2006;177(9):6497–503.CrossRefPubMed
43.
Williman J, Lockhart E, Slobbe L, Buchan G, Baird M. The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. Vaccine. 2006;24(21):4471–4.CrossRefPubMed
44.
Herter S, Osterloh P, Hilf N, Rechtsteiner G, Höhfeld J, Rammensee H-G et al. Dendritic cell aggresome-like-induced structure formation and delayed antigen presentation coincide in influenza virusinfected dendritic cells. J Immunol. 2005;175(2):891–8.
45.
Braciale T, Yap K. Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells. J Exp Med. 1978;147(4):1236–52.
Metadata
Title
Intranasal administration of poly-gamma glutamate induced antiviral activity and protective immune responses against H1N1 influenza A virus infection
Authors
Eun-Ha Kim
Young-Ki Choi
Chul-Joong Kim
Moon-Hee Sung
Haryoung Poo
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2015
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-015-0387-0

Other articles of this Issue 1/2015

Virology Journal 1/2015 Go to the issue

Research

The transcription map of HPV11 in U2OS cells adequately reflects the initial and stable replication phases of the viral genome

Research

Avian influenza H9N2 seroprevalence among pig population and pig farm staff in Shandong, China

Research

Comparative proteomics analysis of Spodoptera frugiperda cells during Autographa californica multiple nucleopolyhedrovirus infection

Research

Proteolytic cleavage analysis at the Murray Valley encephalitis virus NS1-2A junction

Research

Crystal structure of the fibre head domain of bovine adenovirus 4, a ruminant atadenovirus

Research

DAXX modulates human papillomavirus early gene expression and genome replication in U2OS cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits